Grants/Total 4.5 millions of non-dilutive funding:
Ting Therapeutics received the following grants from:
1. National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase I* :
- R43 DC018463-01 (starting 1.2020)
- R43 DC018762-01 (starting 4.2020)
- R43 DC019065-01 (starting 7.2020)
2. State of Nebraska Department of Economic Development (DED Matching Fund (2020- 2021) ).
3. National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase II :
- R44 DC018463 (starting 11.2021)
- R44DC018762-02A1 (starting 08.2022)
4. State of Nebraska Department of Economic Development (DED Matching Fund (2021- 2022) ).
5. State of Nebraska Department of Economic Development (DED Matching Fund (2022- 2023) ).
6. DoD Level I grant (starting 2023).
* Phase I is awarded to determine the merit and feasibility of the proposed R/R&D efforts and to determine the quality of performance of the small business awardee organization prior to providing further Federal support in Phase II. ( SBIR)